RE:RE:“Second mouse gets the cheese “ An Accelerated Approval following the start of ONCY’s planned Phase 3 clinical trial involving pelareorep in combination with the PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) as a first line therapy in advanced/metastatic pancreatic cancer, along with the increasing probability of a near-term M&A, is a fact that certain message board trolls keep trying to understate.